Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
Primary Purpose
HIV Infections, Lipodystrophy, Insulin Resistance
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Avandia administration for 6-12 weeks
Sponsored by
About this trial
This is an interventional diagnostic trial for HIV Infections focused on measuring peripheral fat wasting, truncal adiposity, fat biopsy, muscle biopsy, intravenous lines, blood draws, insulin administration, sugar water, screening
Eligibility Criteria
Inclusion Criteria: 18 years and older Diagnosis of HIV or AIDS Exclusion Criteria: Positive pregnancy test Diagnosis of cancer Acute illness (patients can be enrolled once stable) Hemoglobin less than 7.0 g/dl or acute heart problems Renal function greater than creatinine 1.5 mg/dl Liver dysfunction 3 times normal Use of medications like glucocorticoids and birth control pills Untreated hypertension Diabetes mellitus
Sites / Locations
- University Hospital at Stony Brook New York
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00006185
First Posted
August 22, 2000
Last Updated
March 1, 2010
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT00006185
Brief Title
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
Official Title
Cellular Mechanisms for Metabolic Dysfunction in HIV
Study Type
Interventional
2. Study Status
Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
September 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2003 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
5. Study Description
Brief Summary
With the advent of highly active anti-retroviral therapy(HAART), patients with HIV disease are developing a series of metabolic abnormalities including peripheral fat wasting, increase in truncal fat, high serum triglyceride levels, insulin(a hormone that controls blood sugar) resistance with an increased incidence of Type 2 Diabetes Mellitus and elevated blood pressure. The premise of this study is that abnormalities in the ability of fat and muscle tissue to respond to the hormone insulin may be the cause of the diabetes mellitus, high serum triglyceride levels and abnormal fat distribution. The purpose of the study is to assess how insulin resistant patients with HIV disease are and if their fat and muscle tissue are responding abnormally to insulin. This is done by administering insulin and taking small tissue samples of fat and muscle from the upper thigh and assessing how good insulin acts in these tissues.
Patients with HIV disease will be admitted into the study after undergoing a screening medical history and examination. Once patients qualify, they will have their insulin resistance measured as well as the response of their fat and muscle to insulin; blood levels of glucose (sugar), cholesterol and triglycerides will be measured; body fat will be assessed using radiological tests; a detailed medical history will be obtained to assess risk factors for developing this syndrome.
Patients who are found to be insulin resistant will be offered a trial of an insulin sensitizing agent, called Avandia, for 6-12 weeks. It is hoped that the Avandia will restore the body's ability to respond normally to insulin (as it does in patients with Diabetes) and perhaps improve the fat abnormalities as well. All the same measures will be performed at the end of the course of Avandia as were done at baseline.
Patients who are not insulin resistant will be asked to come back yearly to assess whether they develop insulin resistance over time. This study will continue to recruit patients over the next 3 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, Lipodystrophy, Insulin Resistance
Keywords
peripheral fat wasting, truncal adiposity, fat biopsy, muscle biopsy, intravenous lines, blood draws, insulin administration, sugar water, screening
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Masking
None (Open Label)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Avandia administration for 6-12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years and older
Diagnosis of HIV or AIDS
Exclusion Criteria:
Positive pregnancy test
Diagnosis of cancer
Acute illness (patients can be enrolled once stable)
Hemoglobin less than 7.0 g/dl or acute heart problems
Renal function greater than creatinine 1.5 mg/dl
Liver dysfunction 3 times normal
Use of medications like glucocorticoids and birth control pills
Untreated hypertension
Diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr.Marie Gelato
Organizational Affiliation
SUNY at Stony Brook
Official's Role
Study Director
Facility Information:
Facility Name
University Hospital at Stony Brook New York
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
We'll reach out to this number within 24 hrs